In this week's news roundup from Rheumatology Network, we feature a one-on-one interview with Dr. Michael Lewiecki.

eLearning Expands Osteoporosis Care for Underserved Communities

Rheumatology Director, Yale Lupus Program

Videos

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Lupus Treatment Advances: Agents in the Pipeline

Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.

Lupus Nephritis: Assessing Response to Novel Therapy

The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.

Lupus Nephritis Treatment Advances

The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.

Systemic Lupus Erythematosus Treatment Advances: Anifrolumab

Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.

Systemic Lupus Erythematosus Treatment Advances: Belimumab

Lana Dykes is the Editor of Rheumatology Network. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. She enjoys cooking, yoga, and drawing. 

Daniel J. Lovell, MD, MPH, explains the recent ACR guidelines updates regarding the treatment and management of juvenile idiopathic arthritis and the 
clinical significance of the changes. 


Daniel J. Lovell, MD, MPH: JIA Treatment and Management Guidelines

Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.

Support for Patients With Lupus

Types of tests used to evaluate patients for signs of lupus or disease progression.

Screening Methods to Evaluate for Lupus

Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future. 

Roy Fleischmann, MD: The Future of Biosimilars

Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States. 

Expert Interviews